DPC4 function in human pancreatic cancer

DPC4 在人类胰腺癌中的功能

• 批准号: 6465191
• 负责人: Gloria Huei-Ting Su
• 金额: $ 12.26万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-27 至 2003-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6465191
• 关键词: biological signal transduction; disease /disorder model; gene mutation; genetically modified animals; immunocytochemistry; laboratory mouse; model design /development; neoplasm /cancer genetics; neoplastic process; pancreas neoplasms; reporter genes; transforming growth factors; tumor suppressor genes

DESCRIPTION (provided by applicant): Dr. Gloria H. Su received her Ph.D. from the University of Chicago. During which, she acquired expertise in the development and analysis of knock-out mice in the laboratory of Dr. M. Celeste Simon. In her postdoctoral training in the molecular genetics laboratory of Dr. Scott E. Kern at The Johns Hopkins University, she identified several tumor suppressor genes important to human pancreatic and biliary adenocarcinomas. She joined the faculty at The Johns Hopkins University in July 2000 in the Department of Pathology, and has since combined her two areas of expertise to focus on the development of mouse models for human pancreatic cancer. Most patients with pancreatic cancer are diagnosed at an advanced stage and the current available treatments are not effective in prolonging the patients' survival. New approaches for early diagnoses and treatment could be extensively studied in animal models, if one were available. The continued discoveries of tumor suppressor genes important in pancreatic cancer have now rendered it possible to construct an animal model to further our understanding of pancreatic tumorigenesis. Creating mouse models that mirror human pancreatic tumorigenesis using knock-out and transgenic techniques is one of Dr. Su's major goals. Here she proposes to study the in vivo impact of a tumor-suppressor gene, DPC4 (SMAD4/MADH4), important for human pancreatic cancer, using conditional knock-out mice and a transgenic mouse line carrying DPC4-specific reporter gene. Dr. Su's position at The Johns Hopkins University will provide her access to important resources such as the Transgenic Mouse Core Laboratory, and the intellectual support of a large group of scientists and clinicians dedicated to curing pancreatic cancer. Among them are her sponsors, Drs. Scott E. Kern and Steven D. Leach, who are internationally recognized researchers in the field of pancreatic cancer. From her sponsors, she will continue to gain valuable lessons on the human genetics, pathology of pancreatic cancer, and murine pancreatic development. The clinical backgrounds and focus of her mentors will also assist Dr. Su in framing her research effort so that they remain directly relevant to human pancreatic cancer. With the enormous support of her mentors, colleagues, and the Department of Pathology, Dr. Su will be able to conduct her research in the richest intellectual and resourceful environment possible for academic and research career development.

描述（由申请人提供）：格洛丽亚H博士。苏获得博士学位。从 芝加哥大学。在此期间，她获得了 在M.塞莱斯特 西蒙在她的博士后训练在分子遗传学实验室， 博士斯科特·E约翰霍普金斯大学的克恩发现了几种 对人胰腺和胆道重要的肿瘤抑制基因 腺癌年，她加入了约翰霍普金斯大学的教师队伍。 2000年7月在病理学系工作，此后将两个领域结合起来 专注于开发人类胰腺癌的小鼠模型 癌大多数胰腺癌患者被诊断为晚期胰腺癌。 阶段和目前可用的治疗是不能有效地延长 患者的生存。早期诊断和治疗的新方法可能是 在动物模型中进行了广泛的研究，如果有的话。继续 胰腺癌中重要的肿瘤抑制基因的发现， 使构建动物模型以进一步加深我们的理解成为可能 胰腺肿瘤的发生。创建模仿人类的小鼠模型 使用基因敲除和转基因技术的胰腺肿瘤发生是 博士苏的主要目标。在这里，她建议研究在体内的影响， 肿瘤抑制基因DPC 4（SMAD 4/MADH 4），对人类胰腺重要 使用条件性基因敲除小鼠和携带 DPC 4特异性报告基因。苏博士在约翰霍普金斯的职位 大学将为她提供重要的资源，如 转基因小鼠核心实验室，以及大型 一组致力于治疗胰腺癌的科学家和临床医生。 其中包括她的赞助商，斯科特博士。克恩和史蒂芬D.利奇，谁是 胰腺癌领域国际公认的研究人员。 从她的赞助商，她将继续获得宝贵的经验教训，对人类 胰腺癌的遗传学、病理学和鼠胰腺发育。 导师的临床背景和重点也将帮助苏医生 使她的研究成果与人类直接相关， 胰腺癌在她的导师、同事和 病理学系，苏博士将能够进行她的研究， 为学术界和学术界提供最丰富的智力和资源丰富的环境 研究职业发展。